Evidence map›Paper›PMID 39742417›Full record

ArticleCarcinogenesis2025

Novel inhibitory effect of Omega-3 fatty acids regulating pancreatic cancer progression.

María I Garay, Tamara Mazo, Victoria Ferrero, Nelso N Barotto, Clarisa Lagares, María F Granton, María J Moreira-Espinoza, David C Cremonezzi, Andrea Comba, Mabel N Brunotto and 3 more

Abstract read
In one paragraph

Article in Carcinogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

María I GarayInstituto de Investigaciones en Ciencias de la Salud, INICSA (CONICET - FCM UNC), 5016 Córdoba, Argentina.
Tamara MazoInstituto de Investigaciones en Ciencias de la Salud, INICSA (CONICET - FCM UNC), 5016 Córdoba, Argentina.
Victoria FerreroInstituto de Investigaciones en Ciencias de la Salud, INICSA (CONICET - FCM UNC), 5016 Córdoba, Argentina.
Nelso N BarottoInstituto de Biología Celular y Cátedra de Biología Celular, Histología y Embriología, FCM-UNC, 5016 Córdoba, Argentina.
Clarisa LagaresInstituto de Investigaciones en Ciencias de la Salud, INICSA (CONICET - FCM UNC), 5016 Córdoba, Argentina.
María F GrantonInstituto de Biología Celular y Cátedra de Biología Celular, Histología y Embriología, FCM-UNC, 5016 Córdoba, Argentina.
María J Moreira-EspinozaInstituto de Biología Celular y Cátedra de Biología Celular, Histología y Embriología, FCM-UNC, 5016 Córdoba, Argentina.
David C CremonezziDepartamento de Patología, Hospital Nacional de Clínicas, FCM-UNC, 5000 Córdoba, Argentina.
Andrea CombaDepartment of Pathology, Division Neuropathology, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, United States.
Mabel N BrunottoInstituto de Investigaciones en Ciencias de la Salud, INICSA (CONICET - FCM UNC), 5016 Córdoba, Argentina.
Ezequiel J TolosaSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, United States.
Martín E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN 55905, United States.ORCID 0000-0002-8089-3907
María E PasqualiniInstituto de Investigaciones en Ciencias de la Salud, INICSA (CONICET - FCM UNC), 5016 Córdoba, Argentina.ORCID 0000-0001-8748-5415

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
New Therapuetics for Pancreatic CancerR01CA265050 · NCI · MAYO CLINIC ROCHESTER · PI Mitesh Borad, Martin Ernesto Fernandez-Zapico · 2022 to 2026
$3.0M
UCSD Leading the Advancement of Underrepresented Neuroscientists for Change (LAUNCH) Faculty Development ProgramR25NS117367 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Victoria B Risbrough, Joann Trejo · 2020 to 2026
$1.6M
Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación FONCYT-PICT-2021-GRFTI-00543Consejo Nacional de Investigaciones Científicas y Técnicas - Argentina #22920180100043CONCI NIH HHS P30 CA015083NCI NIH HHS R01 CA265050NINDS NIH HHS R25 NS117367Secretaría de Ciencia y Tecnología de la Universidad Nacional de Córdoba 2018-2020: 411/18, 455/18 472/18
6 · The paper itself

Abstract

Pancreatic cancer is a devastating malignancy in great need of new and more effective treatment approaches. In recent years, studies have indicated that nutritional interventions, particularly nutraceuticals, may provide novel avenues to modulate cancer progression. Here, our study characterizes the impact of ω-3 polyunsaturated fatty acids, eicosapentaenoic acid, and docosahexaenoic acid, as a nutraceutical intervention in pancreatic cancer using a genetically engineered mouse model driven by KrasG12D and Trp53R172H. This model closely resembles human pancreatic carcinogenesis, offering a disease relevant platform for translational research. Our findings showed that ω-3 polyunsaturated fatty acids intervention (using a diet supplemented with 6% cod liver oil) significantly reduced tumor volume as well as lung and liver metastasis and a trend toward improved survival rate compared with control treated mice. This antitumoral effect was accompanied by distinct changes in tumor membrane fatty acid profile and eicosanoids release. Furthermore, the eicosapentaenoic acid and docosahexaenoic acid intervention also reduced malignant histological parameters and induced apoptosis without affecting cell proliferation. Of note is the significant reduction in tumor fibrosis that was associated with decreased levels of Sonic Hedgehog, a major ligand controlling this cellular compartment in pancreatic cancer. All together our results demonstrate the impact of eicosapentaenoic acid and docosahexaenoic acid as antitumor regulators in pancreatic cancer, suggesting potential for ω-3 polyunsaturated fatty acids as a possible antitumoral dietary intervention. This research opens new avenues for integrating nutraceutical strategies in pancreatic cancer management.

Indexed as

Docosahexaenoic AcidsFatty Acids, Omega-3Liver NeoplasmsPancreatic NeoplasmsAnimalsApoptosisCell ProliferationDietary SupplementsDisease Models, AnimalDisease ProgressionEicosapentaenoic AcidHumansLung NeoplasmsMiceProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Docosahexaenoic AcidsEicosapentaenoic AcidFatty Acids, Omega-3Proto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53nutraceutical interventionpancreatic cancerSonic Hedgehogω-3 polyunsaturated fatty acids

Identifiers

PMID39742417
PMCPMC12097994

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.